Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + pertuzumab + pyrotinib + trastuzumab
- Development stage
- Preclinical
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of nab-paclitaxel (an albumin-bound formulation of paclitaxel), pertuzumab (a HER2-targeted monoclonal antibody), pyrotinib (an irreversible pan-ErbB tyrosine kinase inhibitor), and trastuzumab (a HER2-targeted monoclonal antibody). This regimen combines multiple mechanisms of action to target HER2-positive breast cancer, including cytotoxic effects (nab-paclitaxel) and comprehensive HER2 pathway inhibition through both antibody-mediated (pertuzumab and trastuzumab) and small molecule (pyrotinib) approaches.
02
Targets
ERBB4 (Erb-b2 receptor tyrosine kinase 4)HER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)TUBB (Tubulin (alpha and beta subunits))EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on nab-paclitaxel + pertuzumab + pyrotinib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + pertuzumab + pyrotinib + trastuzumab.